Oncolytic Virus Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Oncolytic Virus market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Genelux, CG Oncology, Oncolytics Biotech, Amgen, Daiichio Sankyo, Replimune, Lokon Pharma AB, Binhui Biopharmaceutical Co., Ltd., Genelux GmbH, CG Oncology, Inc., Institut Curie, Biotherapeutics, Turnstone Biologics, Corp., Binhui Biopharmaceutical Co., Ltd., Takara Bio Inc., MediGene, EpicentRx, Inc., Transgene

[Nevada, United States] - DelveInsight's "Oncolytic Virus Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Oncolytic Virus, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Oncolytic Virus Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Oncolytic Virus Market Report:
• The Oncolytic Virus market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Replimune Inc. announced that the purpose of their study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
• In October, 2024: Theriva Biologics SL announced a phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
• In October, 2024: Genelux Corporation announced that the nPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).
• In September, 2024: Replimune Inc. announced that RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
• The total incident cases of selected cancer types in the 7MM were ~6,631,000 in 2023, which is expected to rise at a CAGR of 1.5% during the study period (2020-2034).
• In the 7MM, the highest number of incident cases of selected cancer types were observed in the US with ~2,893,000 cases in 2023. These cases are expected to increase by 2034.
• Oncolytic virus therapies are primarily being developed to treat cancers in relapsed refractory settings. Consequently, these therapies could address nearly 20% of all cancer cases, providing a significant treatable patient pool.
• Key Oncolytic Virus Companies are as follows: Genelux, CG Oncology, Oncolytics Biotech, Amgen, Daiichio Sankyo, Replimune, Lokon Pharma AB, Binhui Biopharmaceutical Co., Ltd., Genelux GmbH, CG Oncology, Inc., Institut Curie, Biotherapeutics, Turnstone Biologics, Corp., Binhui Biopharmaceutical Co., Ltd., Takara Bio Inc., MediGene, EpicentRx, Inc., Transgene
• Key Oncolytic Virus Therapies are as follow: Olvi-Vec (Olvimulogene nanivacirepvec), Cretostimogene grenadenorepvec, Pelareorep, IMLYGIC (T-VEC), DELYTACT (G47Δ), RP1, gemcitabine, nab-paclitaxel, OH2, GL-ONC1, CG0070, Atezolizumab + RP1, JX-594, Ad-MAGEA3, MG1-MAGEA3, Keytruda, TBI-1401(HF10), G207, AdAPT-001, BT-001
• Launching multiple stage Oncolytic Virus pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Oncolytic Virus market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Oncolytic Virus Overview:
Oncolytic viruses are a form of immunotherapy that uses viruses to infect and destroy cancer cells. . These viruses not only naturally target cancer but can also be engineered to deliver additional genes directly into cancer cells, enhancing their tumor-destroying capabilities.

Oncolytic Virus Epidemiology Segmentation:
The Oncolytic Virus market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Oncolytic Virus Target Patient Pool
• Oncolytic Virus Total Incident Cases
• Oncolytic Virus Treated Cases by Cancer Types

For more information about Oncolytic Virus companies working in the treatment market, visit Oncolytic Virus Clinical Trials

Oncolytic Virus Market Insights
Oncolytic viruses, which infect and thrive within cancer cells, replicate rapidly and cause the cells to burst, exposing their contents to the immune system. These viruses can be genetically modified to enhance their tumor-destroying capabilities. The route of administration is critical and depends on the tumor type, impacting the therapy's effectiveness. Delivery methods include intraperitoneal, intrathecal, subcutaneous, intratumoral (offering greater control over viral load and reducing adverse effects), and intravenous (used for treating distant metastases).

Oncolytic Virus Drugs Uptake
• IMLYGIC (T-VEC) by Amgen, the first oncolytic virus, was approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after the initial surgery in 2015.
• DELYTACT is a triple-mutated, replication-conditional herpes simplex virus type 1 (HSV-1) that has been developed to replicate only in cancer cells. In 2021, it received conditional and time limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) to commercialize only at hospitals (served as trial sites) for the treatment of patients with malignant glioma. for a duration of 7 years.
• Olvi-Vec is a modified vaccinia virus that utilizes a triple mode of action: it directly kills cancer cells, stimulates a tumor-specific immune response, and converts the tumor microenvironment from an immunosuppressive (cold state) to an immunoreactive (hot state).
• Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase III clinical trial for the treatment of Bacillus Calmette-Guerin (BCG unresponsive NMIBC.
• Pelareorep, showing promising efficacy, has formed partnerships with leading academic and pharmaceutical collaborators. Its benefits are expected across multiple indications, including breast, gastrointestinal, and hematologic cancers.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Oncolytic Virus Therapies and Key Companies:
• Olvi-Vec (Olvimulogene nanivacirepvec): Genelux
• Cretostimogene grenadenorepvec: CG Oncology
• Pelareorep: Oncolytics Biotech
• IMLYGIC (T-VEC): Amgen
• DELYTACT (G47Δ): Daiichio Sankyo
• RP1: Replimune
• gemcitabine, nab-paclitaxel: Lokon Pharma AB
• OH2: Binhui Biopharmaceutical Co., Ltd.
• GL-ONC1: Genelux GmbH
• CG0070: CG Oncology, Inc.
• Atezolizumab + RP1: Institut Curie
• Ad-MAGEA3, MG1-MAGEA3: Turnstone Biologics, Corp.
• Keytruda: Binhui Biopharmaceutical Co., Ltd.
• TBI-1401(HF10): Takara Bio Inc.
• G207: MediGene
• AdAPT-001: EpicentRx, Inc.
• BT-001: Transgene

Oncolytic Virus Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Oncolytic Virus.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Oncolytic Virus Market Drivers:
• The FDA is granting multiple designations to OVTs in clinical development signaling forthcoming approvals for numerous therapies, highlighting the strength of oncolytic virus therapy.
• Combining OVs with chemotherapy, immunotherapy, and targeted therapies has gained attention for creating a comprehensive strategy to tackle cancer's complex nature.

Oncolytic Virus Market Barriers:
• Delivering the therapy to the tumor is a significant challenge in the growth of the oncolytic virus therapy.
• The lack of understanding of the mechanism of action of the oncolytic virus also hinders the upcoming growth.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Oncolytic Virus Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Oncolytic Virus Companies: Genelux, CG Oncology, Oncolytics Biotech, Amgen, Daiichio Sankyo, Replimune, Lokon Pharma AB, Binhui Biopharmaceutical Co., Ltd., Genelux GmbH, CG Oncology, Inc., Institut Curie, Biotherapeutics, Turnstone Biologics, Corp., Binhui Biopharmaceutical Co., Ltd., Takara Bio Inc., MediGene, EpicentRx, Inc., Transgene
• Key Oncolytic Virus Therapies: Olvi-Vec (Olvimulogene nanivacirepvec), Cretostimogene grenadenorepvec, Pelareorep, IMLYGIC (T-VEC), DELYTACT (G47Δ), RP1, gemcitabine, nab-paclitaxel, OH2, GL-ONC1, CG0070, Atezolizumab + RP1, JX-594, Ad-MAGEA3, MG1-MAGEA3, Keytruda, TBI-1401(HF10), G207, AdAPT-001, BT-001
• Oncolytic Virus Therapeutic Assessment: Current marketed and emerging therapies
• Oncolytic Virus Market Dynamics: Oncolytic Virus Market drivers and Oncolytic Virus barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Oncolytic Virus Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Oncolytic Virus market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Key Highlights from the Report
4 Executive Summary of Oncolytic Viruses
5 Key Events
6 Oncolytic Virus Epidemiology and Market Forecast Methodology
7 Oncolytic Viruses Market Overview at a Glance in the 7MM
8 Background and Overview
9 Target Patient Pool
10 Marketed Oncolytic Virus Drugs
11 Emerging Oncolytic Virus Drugs
12 Oncolytic Virus Market Analysis: 7MM
13 Unmet Needs
14 SWOT Analysis
15 KOL Views
16 Oncolytic Virus Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.